Relief Therapeutics Holding SA, a biopharmaceutical company, announced that its wholly owned subsidiary, APR Applied Pharma Research SA (APR), has executed a definitive agreement with Meta Healthcare Ltd. (Meta), acquiring the worldwide rights, except for the United Kingdom (UK), for a novel dosage form of a prescription drug already approved by the US Food and Drug Administration (FDA) and intended for the treatment of patients with phenylketonuria (PKU). This improved product is expected to improve patient acceptance and compliance. Financial terms of the agreement were not disclosed.
As previously announced, under the terms of the agreement, Meta will provide the technology transfer package and Relief will conduct clinical studies, manufacturing, regulatory submission and commercialization in the US and EU.
